Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

Leiden, The Netherlands, June 30, 2021 – Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company. Dr. Portolano is an experienced...

Next events

21-25 June – BioTrinity 2021

BioTrinity gives an opportunity to share updates on the latest achievments in R&D across all therapy and technology areas.  BGV will be attending BioTrinity 2021 which features a packed LIVE agenda of Panels, Industry Insights, Keynotes, BioLaunchPad Presentations...

Latest investments

Subscribe to BGV news updates

Join our mailing list to receive the latest news and updates from our team.

Privacy Policy

Please check your email to complete your subscription.